The potent and selective RNAi-mediated reduction in β-catenin levels by DCR-BCAT in preclinical models resulted in anti-tumor efficacy in tumors with both APC and other Wnt/β-catenin pathway mutations. The gene discussed is APC; the disease is neoplasm.